Skip to main content
Dr Ruchira Karunadasa
Authored on 3 Sep 2026 by Dr Ruch Karunadasa,Medically reviewed 3 Sep 2026 by Dara O'Malley.Next review due: 3 Sep 2027

Oral vs Injectable Weight Loss Treatments: What's New in 2026?

For years, clinical medical weight management in the UK was defined almost exclusively by weekly injections. Subcutaneous pens such as Wegovy (semaglutide) and Mounjaro (tirzepatide) transformed obesity care, but they also came with trade-offs: needle administration, cold-chain fridge storage, and a weekly schedule.

That landscape has widened. With the MHRA approval of Foundayo (orforglipron) and the rollout of the daily Wegovy pill (oral semaglutide), patients now have clinically proven, needle-free oral options alongside the established weekly pens.

Medical weight management is no longer a one-size-fits-all pathway. Whether you are starting treatment, switching formats, or moving into long-term maintenance, this guide compares daily oral tablets with weekly injections so you can discuss the best fit with a UK-registered clinician.

Foundayo 0.8 mg (orforglipron) once-daily tablet pack

Key takeaways: oral vs injectable weight loss treatments in 2026

  • More choice: UK patients can now choose between weekly GLP-1 injections and daily oral tablets, including Foundayo and the Wegovy pill.
  • Tablets are not identical: Foundayo can be taken at any time, with or without food. The Wegovy pill needs a morning fasting routine with a small sip of water.
  • Injections still lead on average loss: Mounjaro produced the highest average trial weight loss. Wegovy injections remain a well-established GLP-1 option.
  • Adherence matters: The format you can stick to consistently often matters more than headline trial averages.
  • Switching is possible: Patients can move between injections and tablets after a clinical review. It is not an automatic swap.

What's new in 2026?

Two oral options now sit alongside weekly pens in UK private care. Foundayo is a small-molecule, non-peptide GLP-1 tablet approved by the MHRA in August 2026. The Wegovy pill delivers oral semaglutide as a once-daily tablet, with a stricter morning dosing routine than Foundayo.

Weekly injections have not been replaced. They remain the clinical benchmark for average weight-loss efficacy, particularly dual-action Mounjaro. What has changed is that needle-free treatment is no longer a niche alternative: it is a mainstream option for patients who prefer tablets, travel often, or want a maintenance routine that does not rely on fridge storage.

What are the new oral weight loss tablets?

Oral options use GLP-1 receptor pathways to regulate appetite, quieten "food noise," and slow gastric emptying. They aim for the same metabolic benefits as injections, but in tablet form. The two main daily tablets work quite differently in day-to-day practice.

1. Foundayo (orforglipron)

Approved by the MHRA in August 2026, Foundayo is a new generation of GLP-1 therapy.

  • How it works: It is a small-molecule, non-peptide GLP-1 receptor agonist. Because it is non-peptide, the active ingredient is absorbed through the gut without being broken down by stomach acid in the same way peptide tablets are.
  • Daily routine: Taken once daily at any time of day, with or without food. It does not require morning fasting or water-volume restrictions, which makes it a flexible option for travel and shift work.

2. The Wegovy pill (oral semaglutide)

The oral formulation of semaglutide delivers the same active ingredient found in Wegovy injections via a daily tablet.

  • How it works: It is formulated with an absorption enhancer (SNAC) that helps the peptide molecule pass through the stomach lining rather than being broken down.
  • Daily routine: Must be taken first thing in the morning on an empty stomach with a small sip of plain water (no more than 120 ml). You then wait at least 30 minutes before eating, drinking anything else, or taking other oral medicines.

The weekly injections: proven foundations

Weekly pens remain the clinical benchmark for average weight-loss efficacy:

  • Mounjaro (tirzepatide): A dual-action GIP and GLP-1 receptor agonist. By activating two metabolic pathways, it produced the highest average weight loss in clinical trials (around 21% at top doses in SURMOUNT-1).
  • Wegovy injections (semaglutide): A single-hormone GLP-1 injection with an extensive real-world safety track record, producing an average weight reduction of around 15% in STEP-1.

These figures come from separate trials, not a single head-to-head study. Individual results still depend on dose, tolerability, diet, activity, and how consistently you take treatment.

Oral vs injectable: side-by-side comparison

Use the table below as a practical snapshot, then read the lifestyle guidance underneath. Trial averages are rounded headline figures from separate studies.

Feature Foundayo Wegovy pill Mounjaro Wegovy injection
Format Daily tablet Daily tablet Weekly subcutaneous pen Weekly subcutaneous pen
Frequency Once daily Once daily Once every 7 days Once every 7 days
Target hormone GLP-1 GLP-1 GLP-1 + GIP (dual action) GLP-1
Dosing rules Any time, with or without food Morning fasting (30-minute wait) Any time on injection day Any time on injection day
Storage Room temperature (blister pack) Room temperature (blister pack) Fridge for unused pens (2–8°C) Fridge for unused pens (2–8°C)
Average trial weight loss ~11% to 12% (ATTAIN-1) ~15% (OASIS-4) ~21% (SURMOUNT-1) ~15% (STEP-1)
Best for Routine flexibility and travel Needle-free daily habit Maximum average weight loss "Set-and-forget" weekly routine

Which format fits your life?

Choose an oral daily tablet if:

  • You dislike needles: Daily tablets remove injection anxiety completely.
  • You travel frequently: Tablets come in standard blister packs, so you do not need cooler bags, ice packs, or airport liquid checks for your medication.
  • You thrive on daily habits: If you already take daily vitamins or morning medicines, adding a tablet can be a straightforward habit stack.
  • You are in maintenance: Oral options can offer a practical routine to help protect progress once you reach your target, subject to clinical review.

If fasting for 30 minutes every morning would disrupt breakfast, tea, or other tablets, Foundayo is usually the more flexible oral choice. If you already have a strict morning routine and want the same active ingredient as Wegovy injections, the Wegovy pill may suit you better.

Choose a weekly injection if:

  • You prefer "set-and-forget": A single weekly dose means you only need to think about medication once every seven days.
  • You struggle with morning fasting: Weekly injections bypass the gut, so there is no 30-minute wait before tea, coffee, or breakfast.
  • You want maximum average clinical weight loss: For patients with higher starting BMI, dual-action treatments such as Mounjaro continue to lead the published data for overall weight reduction.

Can you switch between injections and tablets?

Yes. Patients often move between formats because of travel, needle preference, side effects, or a move from active weight loss into maintenance.

  • Switching from Mounjaro to Foundayo or the Wegovy pill: The active ingredients differ, so your dose must be mapped clinically. Patients on higher-dose injections generally move onto equivalent mid-to-high oral doses rather than restarting at the lowest strength. Read more in our guide to switching from Mounjaro to Foundayo.
  • Switching from Wegovy injections to the Wegovy pill: Both use semaglutide, so mapping is more straightforward. You typically wait 7 days after your final injection before taking your first daily tablet. See how to switch from injections to the Wegovy pill.

Clinical note: Switching requires a review by a prescriber to check tolerability, map a safe starting dose, and confirm there are no gastrointestinal or other contraindications.

Find what works for you

Medication is a powerful tool to quiet appetite and build momentum, but long-term success still depends on a routine you can sustain. Whether you prefer the convenience of an oral tablet or the established efficacy of a weekly pen, PrivateDoc clinicians can tailor a plan to your health history and lifestyle.

Explore all weight loss treatment options, or start with a free online consultation so a UK-registered prescriber can confirm what is appropriate for you.

Disclaimer: This article is for general information only and does not replace personalised medical advice. Treatment, including any switch between tablets and injections, is only authorised after a successful clinical assessment.

FAQs about oral vs injectable weight loss treatments

Are weight loss pills as effective as injections?

Injections such as Mounjaro show higher average weight loss in clinical trials because of dual-hormone targeting. The Wegovy pill delivered comparable average weight loss to injectable semaglutide (around 15% in OASIS-4), and Foundayo produced meaningful reductions of around 11–12% in ATTAIN-1. Real-world success depends heavily on adherence: if a daily tablet is easier to stick to, your individual results may be just as strong.

Does the Wegovy pill require fasting?

Yes. The Wegovy pill must be taken with a small sip of water on an empty stomach on waking, followed by a 30-minute wait before food, drink, or other oral medicines. Foundayo does not require fasting and can be taken at any time of day, with or without food.

Do oral weight loss tablets need to be kept in the fridge?

No. Both Foundayo and the Wegovy pill are stored at standard room temperature in blister packs, which makes them simpler to manage on holidays and during travel than unused injection pens that need refrigeration.

Can I switch from weekly injections to a daily pill with PrivateDoc?

Yes. During a clinical review you can request a transition. Our prescribers assess your progress, map an equivalent starting dose, and authorise the switch only when it is safe. Check your eligibility to start a consultation.

What's new for oral vs injectable weight loss treatments in 2026?

The main change is wider access to daily tablets. Foundayo (orforglipron) was approved by the MHRA in August 2026 and can be taken with or without food. The Wegovy pill (oral semaglutide) is also available as a needle-free option, with a morning fasting routine. Weekly Wegovy and Mounjaro injections remain important choices, especially where maximum average weight loss is the priority.

How it works

Get personalised care
02.Get personalised care

We'll provide you with a tailored treatment plan from a UK registered doctor

Get next day delivery
03.Get next day delivery

Receive genuine medication shipped discreetly to your door

Did you know?

Over 40% of the population has tried to lose weight at some point in the last 5 years – so you're certainly not alone